ShockWave Medical, Inc. (NASDAQ:SWAV) Director Sells $528,870.00 in Stock

ShockWave Medical, Inc. (NASDAQ:SWAV – Get Rating) Director Frank T. Watkins sold 3,000 shares of the stock in a transaction that occurred on Friday, January 20th. The stock was sold at an average price of $176.29, for a total value of $528,870.00. Following the sale, the director now owns 3,796 shares in the company, valued at $669,196.84. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

ShockWave Medical Trading Down 2.2 %

ShockWave Medical stock traded down $3.91 during mid-day trading on Monday, hitting $176.84. 363,071 shares of the company’s stock were exchanged, compared to its average volume of 525,151. The firm has a market capitalization of $6.39 billion, a P/E ratio of 75.90 and a beta of 1.04. ShockWave Medical, Inc. has a fifty-two week low of $113.36 and a fifty-two week high of $320.54. The company has a quick ratio of 6.02, a current ratio of 7.29 and a debt-to-equity ratio of 0.04. The company’s 50 day simple moving average is $220.84 and its 200-day simple moving average is $248.61.

ShockWave Medical (NASDAQ:SWAV – Get Rating) last issued its quarterly earnings data on Monday, November 7th. The company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.68 by $0.24. The business had revenue of $131.33 million for the quarter, compared to the consensus estimate of $125.85 million. ShockWave Medical had a return on equity of 30.08% and a net margin of 20.48%. On average, equities analysts anticipate that ShockWave Medical, Inc. will post 2.94 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Morgan Stanley decreased their price target on ShockWave Medical from $290.00 to $224.00 and set an “equal weight” rating on the stock in a research report on Friday, January 6th. Wells Fargo & Company downgraded ShockWave Medical from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $300.00 to $235.00 in a report on Monday, December 12th. Bank of America upped their price objective on ShockWave Medical from $260.00 to $310.00 in a report on Monday, November 7th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on ShockWave Medical in a report on Friday, December 16th. They set a “buy” rating and a $285.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $250.89.

Hedge Funds Weigh In On ShockWave Medical

A number of large investors have recently added to or reduced their stakes in the company. Wealth Management Partners LLC increased its holdings in ShockWave Medical by 66.7% during the 4th quarter. Wealth Management Partners LLC now owns 5,000 shares of the company’s stock worth $925,000 after purchasing an additional 2,000 shares in the last quarter. Matisse Capital bought a new position in ShockWave Medical during the 4th quarter worth about $2,071,000. Crossmark Global Holdings Inc. increased its holdings in ShockWave Medical by 17.4% during the 4th quarter. Crossmark Global Holdings Inc. now owns 6,236 shares of the company’s stock worth $1,282,000 after purchasing an additional 924 shares in the last quarter. Fiduciary Alliance LLC bought a new position in ShockWave Medical during the 4th quarter worth about $179,000. Finally, Trifecta Capital Advisors LLC bought a new position in shares of ShockWave Medical in the 4th quarter valued at about $41,000. Institutional investors own 90.56% of the company’s stock.

About ShockWave Medical

(Get Rating)

ShockWave Medical, Inc, a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD.